Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

"These results suggest that anti-obesity medication use, with relatively safe, effective, and sustainable weight loss, may be ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

New research suggests semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could help people reduce their alcohol consumption.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol ...

Semaglutide, known as Ozempic, may reduce alcohol cravings and consumption, offering new addiction treatment possibilities.

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be further influenced by the extensive pipeline of ...

which may be different from the current recommendations for people living with diabetes and obesity. “These data suggest the potential of semaglutide and similar drugs to fill an unmet need for ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.